Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates

分组1 - Anika Therapeutics reported quarterly earnings of $0.31 per share, significantly exceeding the Zacks Consensus Estimate of $0.02 per share, and compared to a loss of $0.03 per share a year ago, representing an earnings surprise of +1,450.00% [1] - The company posted revenues of $30.62 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.03%, and this is a slight increase from year-ago revenues of $30.6 million [2] - Anika has outperformed the S&P 500, with shares increasing about 13.8% since the beginning of the year compared to the S&P 500's gain of 1.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is breakeven on revenues of $28.11 million, and for the current fiscal year, it is $0.26 on revenues of $116.35 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Another company in the same industry, TELA Bio, Inc., is expected to report a quarterly loss of $0.18 per share, with revenues projected to be $21 million, reflecting a 19% increase from the year-ago quarter [9]